Our Promise to You

Guaranteed product quality, expert customer support

Our Promise to You

ONLINE INQUIRY

HDLM-2

Cat.No.: CSC-C0201

Source: Hodgkin lymphoma

Morphology: single, round to polygonal cells in suspension; heterogeneity in cell size, 15-100 μm or larger; many bi- and polynucleated cells

Culture Properties: suspension

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
  • Documents
  • Publications
Cat.No.
CSC-C0201
Description
Established from the pleural effusion of a 74-year-old man with Hodgkin lymphoma (nodular sclerosing, stage IV) in 1982
Source
Hodgkin lymphoma
Recommended Medium
Culture Properties
suspension
Morphology
single, round to polygonal cells in suspension; heterogeneity in cell size, 15-100 μm or larger; many bi- and polynucleated cells
STR DNA Profile
Amelogenin: X,Y
D19S433: 12,15
D5S818: 11
D21S11: 29
D18S51: 14
D6S1043: 11,12
D3S1358: 14,15
D13S317: 11,12
D7S820: 8,10
D16S539: 12
CSF1PO: 11,12
Penta D: 13,14
D2S441: 11
vWA: 19
D8S1179: 13,14
TPOX: 8
Penta E: 12
TH01: 6, 7
D12S391: 15, 23
D2S1338: 17
FGA: 21,23
Karyotype
Remarkable human hypodiploid cell line with large number of rearrangements involving all chromosomes except ch 10 - 36(35-38)<2n>X, der(Y), breakpoints at: 1p21, 1q11, 2p14, 2q37, 3q21, 3p14, 3q11, 3q25.2, 3q27, 4q25, 5q11, 5q35, 6q15/16, 7p14, 8q21.1, 8q
Markers
CD2 +, CD3 -, CD4 (+), CD13 -, CD14 -, CD15 +, CD19 -, CD21 -, CD25 +, CD30 +, HLA-DR +
Sequence Variations
TP53 p.Ser261fs c.?(782delins)
Applications
a. Hodgkin lymphoma related reserach
b. Cell-Based assay
c. In vivo efficacy study
Quality Control
Mycoplasma: Fluorescence (DAPI) test: negative; Mycoplasma specific PCR: negative; Selective biochemical test: negative
Viruses: ELISA: reverse transcriptase negative; PCR: EBV +, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV -
Storage and Shipping
Ship in dry ice.
Store in liquid nitrogen.
BioSafety Level
BSL–1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.,
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The HDLM-2 cell line is a widely used and well-characterized cell line that was established from the pleural effusion of a 74-year-old man diagnosed with Hodgkin lymphoma (HL, nodular sclerosing subtype, stage IV) in 1982. The HDLM-2 cell line represents a specific subtype of HL known as nodular sclerosing, which is one of the most common subtypes of the disease. Nodular sclerosing HL is characterized by the presence of large, tumor-like masses called nodules within the lymph nodes, along with fibrosis or scarring in the surrounding tissues.

The establishment of the HDLM-2 cell line has provided researchers with a valuable tool for studying the biology, pathogenesis, and therapeutic responses of HL. The cell line has been extensively studied and characterized, allowing for in vitro and in vivo investigations of various aspects of the disease. Researchers have used HDLM-2 cells to explore the genetic and molecular alterations present in HL, the signaling pathways involved in its development and progression, and the mechanisms of resistance to treatment.

Effect of ECP on Hodgkin Lymphoma Cell Lines

In HL, tumor eosinophilia indicates poor prognosis, probably caused by eosinophil-induced stimulation of tumor cells. The study was to investigate the effects of eosinophil cationic protein (ECP) on HL tumor cells in vitro. All cell lines were sensitive to ECP but to various degrees. At low concentrations of ECP, HDLM-2 was more sensitive than the L428 and particularly the KMH2 cell lines (Fig. 1). At higher concentrations the opposite was seen, with a more pronounced reduction in SI for L428 and KMH2 as compared to HDLM-2, where a plateau effect was seen.

For HDLM-2 (Fig. 1), a reduction in SI was evident at the lowest ECP concentration tested, 0.004 μM (p < 0.01). At a concentration of 0.018 μM, a plateau in SI of about 70% was reached. No statistically significant difference was determined from the concentration of 0.018 μM ECP and the higher ECP concentrations (ECP up to 1.14 μM) added, thus showing a true plateau.

In an additional experiment, HDLM-2 cells were incubated with or without ECP (LMW-ECP II at 0.07 μM) for 72 hours, after which a new serum-containing medium without ECP was added. Figure 2 shows HDLM-2 cells first after 72 hours of incubation with ECP, and then after an additional 72 hours of culture with serum. The cells continued to grow exponentially after the serum was added; this indicated that ECP caused no injury to the surviving HDLM-2 cells that affected their proliferation.

Fig. 1 The cytotoxic effect of LMW-ECP II on the cell lines HDLM-2 (filled circles), L428 (white squares), and KMH2 (filled triangles). (Glimelius I, et al., 2011)Fig. 1 The cytotoxic effect of LMW-ECP II on the cell lines HDLM-2 (filled circles), L428 (white squares), and KMH2 (filled triangles). (Glimelius I, et al., 2011)

Fig. 2 HDLM-2 cells cultured in 24-well plates with LMW-ECP II at a concentration of 0.07 μM for 72 hours. (Glimelius I, et al., 2011)Fig. 2 HDLM-2 cells cultured in 24-well plates with LMW-ECP II at a concentration of 0.07 μM for 72 hours. (Glimelius I, et al., 2011)

What determines cell viability?

Cell viability assays use a variety of markers as indicators of metabolically active (living) cells. Examples of markers commonly used include measuring ATP levels, measuring the ability to reduce a substrate, and detecting enzymatic/protease activities unique to living cells.

How are HDLM-2 cells used in cancer research?

HDLM-2 cells are utilized in cancer research to investigate the genetic, molecular, and cellular characteristics of nodular sclerosing Hodgkin lymphoma, aiding in the development of targeted treatments.

What insights can studying HDLM-2 cells provide into nodular sclerosing Hodgkin lymphoma?

Research with HDLM-2 cells can offer insights into the disease progression, pathophysiology, and potential therapeutic targets specific to nodular sclerosing Hodgkin lymphoma.

What role do HDLM-2 cells play in preclinical studies and drug development for Hodgkin lymphoma?

HDLM-2 cells serve as a valuable tool in preclinical studies for evaluating drug responses, testing novel therapies, and advancing our understanding of nodular sclerosing Hodgkin lymphoma for improved patient outcomes.

Ask a Question

Average Rating: 4.7    |    3 Scientist has reviewed this product

High-quality

I am extremely gratified with my purchase. The provided tumor cell products are outstanding and unsurpassed in purity and efficiency.

14 Feb 2023


Ease of use

After sales services

Value for money


High quality

The quality and reliability of the HDLM-2 cells from Creative Bioarray have significantly contributed to our research success.

23 Jan 2024


Ease of use

After sales services

Value for money


Invaluable tools

Creative Bioarray has consistently delivered high-quality HDLM-2 cell products for our research needs. These cells have been invaluable in our studies on Hodgkin lymphoma, offering key insights into the genetic and molecular characteristics of nodular sclerosing Hodgkin lymphoma at stage IV.

13 Feb 2023


Ease of use

After sales services

Value for money


Write your own review

  • You May Also Need

For research use only. Not for any other purpose.